Neoleukin Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 0 | $1.58 | $1.58 | $1.58 |
| Q2 2024 | 0 | $1.34 | $1.34 | $1.34 |
| Q3 2024 | 0 | $1.54 | $1.54 | $1.54 |
Neoleukin Therapeutics, Inc. Earnings Date And Information
Neoleukin Therapeutics, Inc. last posted its earnings results on Tuesday, November 14th, 2023. The company reported $-0.41 earnings per share for the quarter, topping analysts' consensus estimates of $-0.8 by $0.39. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Neoleukin Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.01 diluted earnings per share) and currently has a price-to-earnings ratio of -5.86. Neoleukin Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 18th, 2024 based on prior year's report dates.
Neoleukin Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 09/29/2023 | Q3 2023 | -$0.41 | $0 | $0 | ||
| 08/10/2023 | Q2 2023 | -$0.75 | -$0.19 | 0.56 | $0 | $0 |
| 05/08/2023 | Q1 2023 | -$0.90 | -$1.81 | -0.91 | $0 | |
| 03/20/2023 | Q4 2022 | -$0.23 | $0 | |||
| 11/14/2022 | Q3 2022 | -$1.60 | -$1.13 | 0.47 | $0 | |
| 08/09/2022 | Q2 2022 | -$1.50 | -$0.28 | 1.22 | $0 | |
| 05/09/2022 | Q1 2022 | -$1.50 | -$0.28 | 1.22 | $0 | |
| 03/01/2022 | Q4 2021 | -$1.50 | -$0.28 | 1.22 | $6,000 | |
| 11/04/2021 | Q3 2021 | -$1.40 | -$0.28 | 1.12 | $6,000 | |
| 08/05/2021 | Q2 2021 | -$1.35 | -$0.27 | 1.08 | $0 | |
| 05/12/2021 | Q1 2021 | -$1.20 | -$0.27 | 0.93 | $0 | |
| 03/25/2021 | Q4 2020 | -$1.05 | -$0.23 | 0.82 | $451,000 | |
| 11/09/2020 | Q3 2020 | -$1.05 | -$0.04 | 1.01 | $1,000 | |
| 08/12/2020 | Q2 2020 | -$0.95 | -$0.20 | 0.75 | $0 | |
| 05/06/2020 | Q1 2020 | -$1.05 | -$0.18 | 0.87 | $0 | |
| 03/12/2020 | Q4 2019 | -$2.70 | -$0.16 | 2.54 | $0 | |
| 11/13/2019 | Q3 2019 | -$0.20 | -$2.26 | -2.06 | $0 | |
| 08/01/2019 | Q2 2019 | -$0.05 | $0.00 | $0 | ||
| 05/07/2019 | Q1 2019 | -$0.23 | -$0.09 | 0.14 | $0 | |
| 03/07/2019 | Q4 2018 | -$0.79 | -$0.21 | 0.58 | $-25,000,000 |
Neoleukin Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Neoleukin Therapeutics, Inc.'s earnings date?
Neoleukin Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 18th, 2024 based off last year's report dates.
-
Did Neoleukin Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Neoleukin Therapeutics, Inc. (:NLTX) reported $-0.41 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.8 by $0.39.
-
How can I listen to Neoleukin Therapeutics, Inc.'s earnings conference call?
The conference call for Neoleukin Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Neoleukin Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Neoleukin Therapeutics, Inc.'s latest earnings report can be read online.
-
How much profit does Neoleukin Therapeutics, Inc. generate each year?
Neoleukin Therapeutics, Inc. (:NLTX) has a recorded net income of $0. Neoleukin Therapeutics, Inc. has generated $-1.01 earnings per share over the last four quarters.
-
What is Neoleukin Therapeutics, Inc.'s price-to-earnings ratio?
Neoleukin Therapeutics, Inc. (:NLTX) has a price-to-earnings ratio of -5.86 and price/earnings-to-growth ratio is -0.27.
